Search Results

Cosm Medical proudly announces FDA clearance for Gynethotics™ Pessaries, marking it as the first personalized pessary available to patients.

INOVIO today announced that an abstract has been accepted for oral presentation on INO-3107 for the treatment of Recurrent Respiratory Papillomatosis (RRP) at this year’s American Broncho-Esophagological Association (ABEA) program at the Combined Otolaryngology Spring Meetings (COSM) in Boston, Massachusetts.

INOVIO presented new data from a Phase 1/2 trial of INO-3107 (NCT:04398433) for the treatment of HPV 6 and HPV 11-associated Recurrent Respiratory Papillomatosis (RRP) on May 5th as part of the scientific program of the American Broncho-Esophagological Association (ABEA) at the Combined Otolaryngology Spring Meetings (COSM) in Boston, Massachusetts.

Virax Biolabs Group Limited (“Virax” or the “Company”) (Nasdaq: VRAX), an innovative diagnostics company focused on the prevention, detection, and diagnosis of viral diseases, announced that it has signed a Purchase Order with Cosmos Health (Nasdaq: COSM) (“Cosmos”) to launch and market COVID-19 and Influenza A+B Antigen Combo Rapid Detection Kits.

Lyra Therapeutics, Inc. today announced that two new abstracts highlighting additional LANTERN study data evaluating LYR-210 in chronic rhinosinusitis (CRS) have been selected for podium presentations at the upcoming 2022 Combined Otolaryngology Spring Meetings (COSM) being held April 27 – May 1, 2022 in Dallas, Texas.

Lyra Therapeutics, Inc. (Nasdaq: LYRA), today is presenting additional, new data from its LANTERN Phase 2 study of LYR-210 in adult patients with chronic rhinosinusitis (CRS) at the 2022 Combined Otolaryngology Spring Meetings (COSM) being held April 27 – May 1, 2022 in Dallas, Texas.

Cosmos Health Inc. (“Cosmos Health” or the “Company’’) (NASDAQ:COSM) announced today that it has entered into a definitive agreement, subject to customary closing conditions, with a related party to acquire the license and rights for “DIABIT-IS X”, a drug used in the treatment of type-2 diabetes.

Vaxxinity, Inc. announced positive clinical data from its UB-312 program in Parkinson’s disease presented by Jean-Cosme Dodart, PhD, SVP of Research at Vaxxinity in an oral session at the AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s Disease, held virtually and in Lisbon, Portugal from March 5 to March 9, 2024.